These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 39107255)
1. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39107255 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J medRxiv; 2024 Jun; ():. PubMed ID: 38883802 [TBL] [Abstract][Full Text] [Related]
3. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study. Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH; Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806 [TBL] [Abstract][Full Text] [Related]
4. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents. Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB medRxiv; 2024 Mar; ():. PubMed ID: 38585784 [TBL] [Abstract][Full Text] [Related]
5. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. Link-Gelles R; Ciesla AA; Mak J; Miller JD; Silk BJ; Lambrou AS; Paden CR; Shirk P; Britton A; Smith ZR; Fleming-Dutra KE MMWR Morb Mortal Wkly Rep; 2024 Feb; 73(4):77-83. PubMed ID: 38300853 [TBL] [Abstract][Full Text] [Related]
6. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage. Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY medRxiv; 2024 Apr; ():. PubMed ID: 38699313 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148 [TBL] [Abstract][Full Text] [Related]
8. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage. Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY Nat Commun; 2024 Oct; 15(1):8550. PubMed ID: 39362845 [TBL] [Abstract][Full Text] [Related]
9. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023. Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study. Kirsebom FCM; Stowe J; Lopez Bernal J; Allen A; Andrews N J Infect; 2024 Jul; 89(1):106177. PubMed ID: 38719110 [TBL] [Abstract][Full Text] [Related]
11. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1. Wang W; Bhushan G; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Pollett SD; Mitre E; Katzelnick LC; Weiss CD J Virol; 2024 Nov; 98(11):e0094824. PubMed ID: 39365051 [TBL] [Abstract][Full Text] [Related]
12. Omicron variants of SARS-CoV-2: Epidemiological and clinical insights from a tertiary care center in Saudi Arabia. Dubaie B; Aldayel A; Alwethinani S; Alhuthil R; Alhamlan F; Alghamdi S; Alsuhaibani M; Aljumaah S; AlYabes O; AlBanyan E; Al-Hajjar S J Infect Public Health; 2024 Jun; 17(6):961-966. PubMed ID: 38608457 [TBL] [Abstract][Full Text] [Related]
13. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection. Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Gayed J; Bangad V; Xu X; Mensa F; Cutler M; Türeci Ö; Şahin U; Modjarrad K; Swanson KA; Anderson AS; Gurtman A; Kitchin N; Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066372 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Huiberts AJ; Hoeve CE; de Gier B; Cremer J; van der Veer B; de Melker HE; van de Wijgert JH; van den Hof S; Eggink D; Knol MJ Euro Surveill; 2024 Mar; 29(10):. PubMed ID: 38456217 [TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890 [TBL] [Abstract][Full Text] [Related]
17. Risks of SARS-CoV-2 JN.1 Infection and COVID-19-Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study. Chong C; Wee LE; Jin X; Zhang M; Malek MIA; Ong B; Lye D; Chiew CJ; Tan KB Clin Infect Dis; 2024 Nov; 79(5):1190-1196. PubMed ID: 38922669 [TBL] [Abstract][Full Text] [Related]
18. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396 [TBL] [Abstract][Full Text] [Related]
19. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters. Soudani N; Bricker TL; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Davis-Gardner M; Suthar MS; Ellebedy AH; Boon ACM J Virol; 2024 Oct; 98(10):e0052824. PubMed ID: 39230305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]